Literature DB >> 22641564

JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Linda M Scott1, Vivienne I Rebel.   

Abstract

The myeloproliferative neoplasms (MPNs) are a particularly useful model for studying mutation accumulation in neoplastic cells, and the mechanisms underlying their acquisition. This review summarizes our current understanding of the molecular defects present in patients with an MPN, and the effects of mutations targeting Janus kinase 2 (JAK2)-mediated intracellular signaling on DNA damage and on the elimination of mutation-bearing cells by programmed cell death. Moreover, we discuss findings that suggest that the acquisition of disease-initiating mutations in hematopoietic stem cells of some MPN patients may be the consequence of an inherent genomic instability that was not previously appreciated.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22641564      PMCID: PMC3479366          DOI: 10.1002/ajh.23243

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  111 in total

1.  Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.

Authors:  Linda M Scott; Philip A Beer; Anthony J Bench; Wendy N Erber; Anthony R Green
Journal:  Br J Haematol       Date:  2007-11       Impact factor: 6.998

2.  Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.

Authors:  C M Butcher; U Hahn; L B To; J Gecz; E J Wilkins; H S Scott; P G Bardy; R J D'Andrea
Journal:  Leukemia       Date:  2007-10-04       Impact factor: 11.528

Review 3.  BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts.

Authors:  Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2008-04

4.  Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.

Authors:  Daniela Pietra; Sai Li; Angela Brisci; Francesco Passamonti; Elisa Rumi; Alexandre Theocharides; Maurizio Ferrari; Heinz Gisslinger; Robert Kralovics; Laura Cremonesi; Radek Skoda; Mario Cazzola
Journal:  Blood       Date:  2007-11-05       Impact factor: 22.113

5.  Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.

Authors:  Ralph Tiedt; Hui Hao-Shen; Marta A Sobas; Renate Looser; Stephan Dirnhofer; Jürg Schwaller; Radek C Skoda
Journal:  Blood       Date:  2007-12-26       Impact factor: 22.113

6.  Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Authors:  Karl Sotlar; Anja Bache; Florian Stellmacher; Burkhard Bültmann; Peter Valent; Hans-Peter Horny
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

7.  Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.

Authors:  K Shide; H K Shimoda; T Kumano; K Karube; T Kameda; K Takenaka; S Oku; H Abe; K S Katayose; Y Kubuki; K Kusumoto; S Hasuike; Y Tahara; K Nagata; T Matsuda; K Ohshima; M Harada; K Shimoda
Journal:  Leukemia       Date:  2007-11-22       Impact factor: 11.528

8.  Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.

Authors:  Sai Li; Robert Kralovics; Gennaro De Libero; Alexandre Theocharides; Heinz Gisslinger; Radek C Skoda
Journal:  Blood       Date:  2008-01-14       Impact factor: 22.113

9.  The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.

Authors:  Melanie J Percy; Linda M Scott; Wendy N Erber; Claire N Harrison; John T Reilly; Frank G C Jones; Anthony R Green; Mary Frances McMullin
Journal:  Haematologica       Date:  2007-12       Impact factor: 9.941

10.  Chromatin structure regulates gene conversion.

Authors:  W Jason Cummings; Munehisa Yabuki; Ellen C Ordinario; David W Bednarski; Simon Quay; Nancy Maizels
Journal:  PLoS Biol       Date:  2007-10       Impact factor: 8.029

View more
  5 in total

1.  ERK1/2 inhibition enhances apoptosis induced by JAK2 silencing in human gastric cancer SGC7901 cells.

Authors:  Cuijuan Qian; Jun Yao; Jiji Wang; Lan Wang; Meng Xue; Tianhua Zhou; Weili Liu; Jianmin Si
Journal:  Mol Cell Biochem       Date:  2013-11-01       Impact factor: 3.396

2.  Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations.

Authors:  Stephen E Langabeer; Karl Haslam; Jennifer Linders; Melanie J Percy; Eibhlin Conneally; Amjad Hayat; Brian Hennessy; Maeve Leahy; Karen Murphy; Margaret Murray; Fionnuala Ni Ainle; Patrick Thornton; Jeremy Sargent
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

Review 3.  Neutrophil Death in Myeloproliferative Neoplasms: Shedding More Light on Neutrophils as a Pathogenic Link to Chronic Inflammation.

Authors:  Dragana Marković; Irina Maslovarić; Dragoslava Djikić; Vladan P Čokić
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

4.  Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.

Authors:  Renata Mendes de Freitas; Carlos Magno da Costa Maranduba
Journal:  Rev Bras Hematol Hemoter       Date:  2015-06-09

Review 5.  Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.

Authors:  Lasse Kjær
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.